Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

August 3, 2018 5:04 PM UTC

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and its Astex Pharmaceuticals Inc. subsidiary said first-line treatment with guadecitabine (formerly SGI-110) missed the co-primary endpoints in the Phase III ASTRAL-1 trial to treat previously untreated acute myelogenous leukemia (AML).

The companies plan to continue evaluating guadecitabine in the Phase III ASTRAL-2 trial for relapsed or refractory AML following intensive chemotherapy and the Phase III ASTRAL-3 trial to treat myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) after failure of azacitidine, decitabine or both...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article